Michael Robert Ballinger

Array ( [id] => 16296251 [patent_doc_number] => 20200281974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => PD1-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AS AN IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/650884 [patent_app_country] => US [patent_app_date] => 2018-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12434 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16650884 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17996683 [patent_doc_number] => 11497769 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => Anti-CD19 antibodies [patent_app_type] => utility [patent_app_number] => 16/649157 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 30 [patent_no_of_words] => 28228 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 587 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282671 [patent_doc_number] => 20200276273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => METHOD FOR TREATING MYELOID LEUKEMIA [patent_app_type] => utility [patent_app_number] => 16/649914 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16252128 [patent_doc_number] => 20200261502 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => GENETICALLY ENGINEERED T CELL AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/645247 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19340 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645247 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18070609 [patent_doc_number] => 11529425 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-20 [patent_title] => Immunoconjugates comprising signal regulatory protein alpha [patent_app_type] => utility [patent_app_number] => 16/645064 [patent_app_country] => US [patent_app_date] => 2018-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 26 [patent_no_of_words] => 24019 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 496 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16072431 [patent_doc_number] => 20200190202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => Reprogramming of CD8 T Cells with CXCL12 Signaling Inhibitors [patent_app_type] => utility [patent_app_number] => 16/637972 [patent_app_country] => US [patent_app_date] => 2018-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16637972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16153759 [patent_doc_number] => 20200215112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => CHIMERIC ANTIGEN RECEPTOR FOR HER2/NEU AND T-CELLS EXPRESSING SAME [patent_app_type] => utility [patent_app_number] => 16/637503 [patent_app_country] => US [patent_app_date] => 2018-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16637503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236803 [patent_doc_number] => 20200254037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES WITH AN ANTI PD-L1 ANTIBODY AND AN ONCOLYTIC VIRUS [patent_app_type] => utility [patent_app_number] => 16/637600 [patent_app_country] => US [patent_app_date] => 2018-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16637600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16108487 [patent_doc_number] => 20200206266 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => USE OF FLT3 CAR-T CELLS AND FLT3 INHIBITORS TO TREAT ACUTE MYELOID LEUKEMIA [patent_app_type] => utility [patent_app_number] => 16/633132 [patent_app_country] => US [patent_app_date] => 2018-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27647 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -99 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16633132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15831977 [patent_doc_number] => 20200131270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => COMBINATION USE OF INHIBITOR TARGETING PD-1/PD-L1 AND COX-2 INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/630908 [patent_app_country] => US [patent_app_date] => 2018-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26159 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16630908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16176956 [patent_doc_number] => 20200223924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => DOSAGE REGIMENS FOR ANTI-TIM-3 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/626148 [patent_app_country] => US [patent_app_date] => 2018-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58045 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16626148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497429 [patent_doc_number] => 20230220063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => IL-1BETA BINDING ANTIBODIES FOR USE IN TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/624130 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16624130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720139 [patent_doc_number] => 20210087286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS [patent_app_type] => utility [patent_app_number] => 16/623750 [patent_app_country] => US [patent_app_date] => 2018-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16623750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18043698 [patent_doc_number] => 11517632 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-06 [patent_title] => Anti-Her2 single chain antibody and coding sequence and use thereof [patent_app_type] => utility [patent_app_number] => 16/624403 [patent_app_country] => US [patent_app_date] => 2018-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 7 [patent_no_of_words] => 12000 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16624403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545317 [patent_doc_number] => 11718657 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => T cell receptors [patent_app_type] => utility [patent_app_number] => 16/624853 [patent_app_country] => US [patent_app_date] => 2018-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 9 [patent_no_of_words] => 14296 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16624853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13552571 [patent_doc_number] => 20180327833 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => BIOFUNCTIONALIZED NANOSHELL IMMOBILIZED MICROARRAYS AND APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 15/979185 [patent_app_country] => US [patent_app_date] => 2018-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10239 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15979185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18232111 [patent_doc_number] => 11596655 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => Activation of natural cytotoxicity receptor 2 (NCR2) [patent_app_type] => utility [patent_app_number] => 16/608708 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 84 [patent_figures_cnt] => 125 [patent_no_of_words] => 30398 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16608708 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18230766 [patent_doc_number] => 20230069760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/606246 [patent_app_country] => US [patent_app_date] => 2018-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67338 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17007026 [patent_doc_number] => 20210238187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/604837 [patent_app_country] => US [patent_app_date] => 2018-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15553239 [patent_doc_number] => 20200061031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => METHOD FOR TREATING EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 16/485777 [patent_app_country] => US [patent_app_date] => 2018-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13263 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16485777 [rel_patent_id] =>[rel_patent_doc_number] =>)